Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Change in Account Payables (2020 - 2022)

Atea Pharmaceuticals has reported Change in Account Payables over the past 3 years, most recently at $1.4 million for Q4 2022.

  • Quarterly results put Change in Account Payables at $1.4 million for Q4 2022, up 108.12% from a year ago — trailing twelve months through Dec 2022 was -$2.0 million (down 119.27% YoY), and the annual figure for FY2025 was $8.5 million, up 4019.9%.
  • Change in Account Payables for Q4 2022 was $1.4 million at Atea Pharmaceuticals, up from -$12.8 million in the prior quarter.
  • Over the last five years, Change in Account Payables for AVIR hit a ceiling of $12.7 million in Q2 2021 and a floor of -$17.7 million in Q4 2021.
  • Median Change in Account Payables over the past 3 years was $1.2 million (2020), compared with a mean of $651500.0.
  • Peak annual rise in Change in Account Payables hit 2588.0% in 2021, while the deepest fall reached 322.7% in 2021.
  • Atea Pharmaceuticals' Change in Account Payables stood at -$4.2 million in 2020, then crashed by 322.7% to -$17.7 million in 2021, then soared by 108.12% to $1.4 million in 2022.
  • The last three reported values for Change in Account Payables were $1.4 million (Q4 2022), -$12.8 million (Q3 2022), and $10.2 million (Q2 2022) per Business Quant data.